Andrew Hedin is a vice president in Bessemer’s Cambridge office where he focuses on investments in healthcare.
Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund, as well as Leerink Partners.
He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.
Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases.
AccuVein is a global leader in medical imaging solutions.
Bright Health is a consumer focused health plan offering simple and affordable health insurance.
Collective Medical empowers care teams to improve patient outcomes by closing the communication gaps that undermine patient care.
Docent Health helps health systems design and implement better, more human patient experiences.
Fractyl develops innovative medical device solutions for the treatment of chronic diseases.
Subtle Medical uses AI to redefine the standards for medical imaging, making it faster, safer, and smarter.
Groups helps people recover from opiate use through therapy and medication.
Qventus optimizes decisions in hospitals in real time to reduce costs, improve quality and experience.
TScan Therapeutics is harnessing novel T cell systems to extend the promise of immunotherapy